company background image
PCIB

PCI Biotech Holding OB:PCIB Stock Report

Last Price

kr4.11

Market Cap

kr153.2m

7D

-2.8%

1Y

-82.9%

Updated

15 May, 2022

Data

Company Financials
PCIB fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PCIB Stock Overview

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform.

PCI Biotech Holding Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for PCI Biotech Holding
Historical stock prices
Current Share Pricekr4.11
52 Week Highkr28.92
52 Week Lowkr4.00
Beta1.86
1 Month Change-6.06%
3 Month Change-18.71%
1 Year Change-82.91%
3 Year Change-85.75%
5 Year Change-82.07%
Change since IPO-77.19%

Recent News & Updates

Apr 21
We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully

We Think PCI Biotech Holding (OB:PCIB) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Dec 16
We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely

We're Hopeful That PCI Biotech Holding (OB:PCIB) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

PCIBNO BiotechsNO Market
7D-2.8%-6.1%-1.2%
1Y-82.9%-48.9%12.6%

Return vs Industry: PCIB underperformed the Norwegian Biotechs industry which returned -48.9% over the past year.

Return vs Market: PCIB underperformed the Norwegian Market which returned 12.6% over the past year.

Price Volatility

Is PCIB's price volatile compared to industry and market?
PCIB volatility
PCIB Average Weekly Movement7.8%
Biotechs Industry Average Movement8.9%
Market Average Movement7.4%
10% most volatile stocks in NO Market12.4%
10% least volatile stocks in NO Market4.2%

Stable Share Price: PCIB is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: PCIB's weekly volatility has decreased from 13% to 8% over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a14Per Waldayhttps://www.pcibiotech.com

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin.

PCI Biotech Holding Fundamentals Summary

How do PCI Biotech Holding's earnings and revenue compare to its market cap?
PCIB fundamental statistics
Market Capkr153.22m
Earnings (TTM)-kr87.63m
Revenue (TTM)kr717.00k

213.8x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PCIB income statement (TTM)
Revenuekr717.00k
Cost of Revenuekr0
Gross Profitkr717.00k
Other Expenseskr88.35m
Earnings-kr87.63m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 31, 2022

Earnings per share (EPS)-2.35
Gross Margin100.00%
Net Profit Margin-12,221.76%
Debt/Equity Ratio0%

How did PCIB perform over the long term?

See historical performance and comparison

Valuation

Is PCI Biotech Holding undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1.73x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PCIB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PCIB's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: PCIB is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.

PE vs Market: PCIB is unprofitable, so we can't compare its PE Ratio to the Norwegian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PCIB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PCIB is good value based on its PB Ratio (1.7x) compared to the NO Biotechs industry average (3.9x).


Future Growth

How is PCI Biotech Holding forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


65.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as PCI Biotech Holding has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has PCI Biotech Holding performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-20.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PCIB is currently unprofitable.

Growing Profit Margin: PCIB is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PCIB is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.

Accelerating Growth: Unable to compare PCIB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PCIB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-5.2%).


Return on Equity

High ROE: PCIB has a negative Return on Equity (-98.68%), as it is currently unprofitable.


Financial Health

How is PCI Biotech Holding's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PCIB's short term assets (NOK107.7M) exceed its short term liabilities (NOK19.5M).

Long Term Liabilities: PCIB's short term assets (NOK107.7M) exceed its long term liabilities (NOK1.1M).


Debt to Equity History and Analysis

Debt Level: PCIB is debt free.

Reducing Debt: PCIB has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PCIB has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PCIB has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 18.2% each year.


Dividend

What is PCI Biotech Holding current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PCIB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PCIB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PCIB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCIB's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PCIB has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.9yrs

Average management tenure


CEO

Per Walday (61 yo)

14.08yrs

Tenure

Dr. Per Walday, Ph D., has been the Chief Executive Officer at PCI Biotech AS since 2008. He serves as Chief Executive Officer at EXACT Therapeutics AS since March 28, 2022.Dr. Walday has been the Chief E...


CEO Compensation Analysis

Compensation vs Market: Per's total compensation ($USD296.79K) is about average for companies of similar size in the Norwegian market ($USD330.08K).

Compensation vs Earnings: Per's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PCIB's management team is seasoned and experienced (5.9 years average tenure).


Board Members

Experienced Board: PCIB's board of directors are considered experienced (5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PCI Biotech Holding ASA's employee growth, exchange listings and data sources


Key Information

  • Name: PCI Biotech Holding ASA
  • Ticker: PCIB
  • Exchange: OB
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: kr153.225m
  • Shares outstanding: 37.33m
  • Website: https://www.pcibiotech.com

Number of Employees


Location

  • PCI Biotech Holding ASA
  • UllernchaussEen 64
  • Oslo
  • Oslo
  • 379
  • Norway

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.